Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Henry Schein (HSIC) delivered earnings and revenue surprises of 49.40% and 3.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q1 Earnings and Revenues Surpass Estimates

Shares of Henry Schein (NASDAQ:HSIC) decreased 3.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 31.91% over the past year to $1.24, which beat the estimate of $0.85.

Recap: Henry Schein Q1 Earnings

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. reports record first-quarter 2021 financial results from continuing operations.

Henry Schein Reports Record First-Quarter 2021 Financial Results from Continuing Operations

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to present at the Bank of America Securities 2021 virtual health care conference.

Henry Schein to Present at the Bank of America Securities 2021 Virtual Health Care Conference

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein CEO Stanley Bergman submits letter to congressional subcommittee supporting expanded COVID vaccine distribution.

Henry Schein CEO Stanley M. Bergman Submits Letter to Congressional Subcommittee Supporting Expanded COVID Vaccine Distribution

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to Webcast First Quarter 2021 Conference Call on Tuesday, May 4, 2021 at 10:00 A.M. Eastern Time

Henry Schein to Webcast First Quarter 2021 Conference Call on Tuesday, May 4, 2021 at 10:00 A.M. Eastern Time

Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.

Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. announced a majority investment in Stradis Medical, LLC to advance its commitment to the growing ambulatory surgery market.

Henry Schein Strengthens Its Commitment to Ambulatory Surgery Market With a Majority Investment in Stradis Healthcare

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today its partnership with the Black Coalition Against COVID-19 (BCAC) in support of the BCAC's recent virtual town hall, “Making It Plain: A COVID-19 Town Hall for Minority Health Professionals.” Henry Schein's collaboration with the BCAC reinforces the Company's advocacy for vaccine equity and the vital role primary-care physicians and other office-based health care practitioners play in expanding COVID-19 vaccinatio

Henry Schein Furthers Its Commitment to Accelerating Vaccine Equity by Partnering With the Black Coalition Against COVID-19

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Henry Schein (HSIC) Up 4.8% Since Last Earnings Report: Can It Continue?

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein CEO issues statement encouraging Biden-Harris Administration to include primary-care physicians in vaccine dissemination process.

Henry Schein CEO Stanley M. Bergman Issues Statement of Support for Congressional Effort to Expand COVID Vaccine Distribution

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares Foundation Launches Next Phase of the ‘Wearing is Caring' Campaign and Announces New Support for Special Olympics

Henry Schein Cares Foundation Launches Next Phase of the ‘Wearing is Caring' Campaign and Announces New Support for Special Olympics

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. announces reinstatement of share repurchase program.

Henry Schein Announces Reinstatement of Share Repurchase Program

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has donated more than 10 million items of personal protective equipment (PPE) and supplies worth millions of dollars to enhance the safety of front-line health care professionals, social service providers, underserved populations, and people with intellectual disabilities. The donation includes face shields, hand sanitizer, i

Henry Schein Donates More Than 10 Million Personal Protective Equipment Items to Non-Governmental Organizations for Front-Line Health Care Workers and Social Service Providers

NEW YORK--(BUSINESS WIRE)--Grin partners with Henry Schein Orthodontics and launches remote consultations that enables asynchronous consults and enhanced visibility.

Grin Partners with Henry Schein Orthodontics and Launches Remote Orthodontic Consultations

Boston Scientific

We think that ​Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific.

Henry Schein Likely To Offer Better Returns Compared To Boston Scientific Stock

Schein's 2020 was disappointing due to a very weak second quarter, but the company started to gain momentum by the end of the year. Schein is expecting to get back to its 2019 performance this year. This means a $3.50 EPS and likely a FCFPS of around $4.35.

Henry Schein's Post-Earnings Blues Not Justified

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. has been recognized by Ethisphere as one of the 2021 World's Most Ethical Companies.

Ethisphere Announces Henry Schein, Inc. as One of the 2021 World's Most Ethical Companies for the 10th Time

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. announced that it will virtually present at the 2021 Barclays Global Healthcare Conference on March 9, 2021.

Henry Schein to Present at the 2021 Barclays Global Healthcare Conference

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in the Southern, Mid-Atlantic, and Northeastern states that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the winter storms. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Member

Henry Schein Opens Customer Assistance Hotline in Response to Winter Storms Across the United States

Align Technology

Becton, Dickinson and Co.

McKesson

The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)

4 Dental Stocks to Watch on Likely Industry Turnaround

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q4 2020 Results - Earnings Call Transcript

Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip

Henry Schein (HSIC) delivered earnings and revenue surprises of 4.17% and 10.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates

Shares of Henry Schein (NASDAQ:HSIC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 3.09% year over year to $1.00, which beat the estimate of $0.99.

News for Henry Schein Stock (HSIC)